Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson's Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study.

ABSTRACT:

Objective

We aimed to analyze the real-world use of COMT inhibitors associated with levodopa in patients with Parkinson's disease (PD) who present early fluctuations and to explore whether early COMT inhibition optimizes treatment outcomes.

Methods

REONPARK is an ongoing 2-year prospective observational study. We included patients diagnosed with PD who presented signs of end-of-dose motor fluctuations for <2 years and started COMT inhibitors according to clinical practice. Outcomes included the clinician and patient global impression of change (CGI-C, PGI-C), the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the Parkinson's Disease Questionnaire-8 (PDQ-8), Non-Motor Symptoms Scale (NMSS), 19-Symptom Wearing-off Ques

SUBMITTER: Lopez-Manzanares L 

PROVIDER: S-EPMC12110095 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature